Epicrispr plans to start a Phase 1 trial in New Zealand this year.
Company Description
Epicrispr Biotechnologies is developing a first-of-its-kind genetic medicine for facioscapulohumeral muscular dystrophy (FSHD) using CRISPR tools to silence a gene involved in the disease's progression.